Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | REN | P00797 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.47 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20347975 | 0.91 | REN (0.58) | ALOX5LTA4HRENCNR2TRPM8 | |
| SCHEMBL20347999 | 0.82 | ALOX5 (0.54) | ALOX5LTA4HRENCNR2NPC1 | |
| SCHEMBL2226376 | 0.81 | SMN1; SMN2 (0.51) | ALOX5LTA4HRENTDP1NPC1 | |
| SCHEMBL2224578 | 0.81 | SMN1; SMN2 (0.54) | ALOX5LTA4HRENNPC1TSHR | |
| SCHEMBL6228526 | 0.80 | LPAR1 (0.60) | ALOX5LTA4HNPC1RAB9ALPAR1 | |
| SCHEMBL3554465 | 0.80 | ALOX5 (0.59) | ALOX5LTA4HTDP1NPC1RAB9A | |
| SCHEMBL20347743 | 0.80 | SIGMAR1 (0.57) | ALOX5LTA4HTDP1ACHELTB4R2 | |
| SCHEMBL6176103 | 0.77 | ACHE (0.53) | ALOX5LTA4HTDP1TSHRTRPM8 | |
| SCHEMBL7004788 | 0.77 | BMP1 (0.66) | TDP1CNR2MAPK1 | |
| SCHEMBL9831172 | 0.77 | USP2 (0.46) | ALOX5LTA4HTDP1TSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340107-A1 | NRF2 ACTIVATOR | BIOGEN MA INC. | 2021-11-04 | — | — | US | disclosed |
| EP-3875450-A1 | NRF2 ACTIVATOR | Biogen MA Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3562816-B1 | NRF2 ACTIVATOR | BIOGEN MA INC (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2018125880-A1 | NRF2 ACTIVATOR | BIOGEN MA INC. (US) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340107-A1 | NRF2 ACTIVATOR | NFE2L2, KEAP1, NQO1 | ALOX5 566/4885LTA4H 1319/4885REN 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.